← All trials
NCT05496595
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 26, 2022
- Primary completion
- Sep 30, 2024
- Completion date
- Oct 31, 2024
- First posted
- Aug 11, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 192
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- DynamiCure BiotechnologyLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.